Amanta Healthcare Makes Modest Debut with 7% Premium, Meeting Grey Market Expectations

Amanta Healthcare Limited, the pharmaceutical company specializing in sterile liquid products and medical devices, made a modest debut on BSE and NSE on September 9, 2025. After closing its IPO bidding between September 1-3, 2025, the company commenced trading with a 7.14% premium at ₹135 on NSE and 6.3% premium at ₹134 on BSE, matching grey market expectations and reflecting cautious investor sentiment towards the pharmaceutical manufacturing sector.

Amanta Healthcare Listing Details

Amanta Healthcare Limited launched its IPO at ₹126 per share with a minimum investment of 119 shares costing ₹14,994. The IPO received an overwhelming response with a subscription of 82.60 times - NII leading at an exceptional 209.40 times, retail investors at 54.96 times, and QIB at 35.86 times, indicating strong investor interest across all categories in the pharmaceutical business, particularly from non-institutional investors.

First-Day Trading Performance Outlook

Listing Price: The Amanta Healthcare share price opened at ₹135 on NSE and ₹134 on BSE, representing premiums of 7.14% and 6.3% respectively from the issue price of ₹126, delivering modest gains for investors and meeting grey market premium expectations of ₹9.

Growth Drivers and Challenges

Growth Drivers:

• Specialised Manufacturing Technology: Advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies for sterile liquid products providing competitive advantages and manufacturing efficiency.
• Diversified Product Portfolio: Comprehensive range including IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, and medical devices serving multiple therapeutic segments.
• Strong Global Presence: Products registered in 19 countries with exports to 21 countries in Africa, Latin America, U.K., and beyond, providing geographical diversification and revenue stability.
• Established Distribution Network: Marketing through 320 distributors and stockists in India with experienced sales teams across national, international, and product partnering business units.

Challenges:

• Stagnant Revenue Growth: Revenue remained nearly flat with a 2% decline to ₹276.09 crore in FY25, indicating challenges in top-line expansion and market competitiveness.
• High Debt Burden: Debt-to-equity ratio of 2.02 with total borrowings of ₹195 crore creating significant financial leverage concerns affecting cash flow management and expansion capabilities.
• Aggressive Valuation Metrics: Post-IPO P/E ratio of 46.59 and Price to Book Value of 3.77 indicating expensive pricing requiring sustained exceptional performance to justify investor expectations.
• Low Profitability Margins: PAT margin of only 3.86% indicating thin profit margins and operational efficiency challenges in the competitive pharmaceutical manufacturing market.

Utilisation of IPO Proceeds

• Manufacturing Expansion: ₹70 crore for capital expenditure towards civil construction and equipment for new SteriPort manufacturing line at Hariyala, Gujarat, enhancing production capabilities.
• Additional Manufacturing Line: ₹30.13 crore for capital expenditure towards new SVP (Small Volume Parenteral) manufacturing line setup expanding product portfolio and capacity.
• General Corporate Purposes: ₹6.60 crore for general corporate purposes supporting business operations and strategic initiatives.

Financial Performance of Amanta Healthcare

• Revenue: ₹276.09 crore for FY25, showing marginal decline of 2% from ₹281.61 crore in FY24, reflecting challenging market conditions despite strong subscription response. 
• Net Profit: ₹10.50 crore in FY25, representing exceptional growth of 189% from ₹3.63 crore in FY24, indicating significant operational improvements and cost management. 
• Financial Metrics: Moderate ROE of 12.42%, solid ROCE of 13.72%, high debt-to-equity ratio of 2.02, reasonable RoNW of 10.89%, low PAT margin of 3.86%, strong EBITDA margin of 22.11%, high Price to Book Value of 3.77, and market capitalisation of ₹520.31 crore.